Citations

Showing 10 of 108104 citations.

Development of Advanced Heart Failure: A Population-Based Study
Subramaniam, Anna , Weston, Susan A., Killian, Jill M. , Schulte, Phillip J. , Roger, Véronique L. , Redfield, Margaret M., Blecker, Saul B., Dunlay, Shannon M. , Blecker, Saul , Subramaniam, Anna V , Dunlay, Shannon , Weston, Susan A., Killian, Jill M , Schulte, Phillip , Redfield, Margaret M.

Mayo Clinic

Circulation: Heart Failure | March 25, 2022 | Volume: 15 | Issue: 5 | Pages: No page available

10.1161/circheartfailure.121.009218 | PMID 35332793 Get It

Background: Some patients with heart failure (HF) will go on to develop advanced HF, characterized by severe HF symptoms despite attempts to optimize medical therapy. The goals of this study were to examine the risk of developing advanced HF in patients with newly diagnosed HF, identify risk factors for developing advanced HF, and evaluate the impact of advanced HF on outcomes. Methods: This was a population-based, retrospective cohort study of Olmsted County, Minnesota, residents with a new clinical diagnosis of HF between 2007 and 2017. Risk factors for the development of advanced HF (2018 European Society of Cardiology criteria) were examined using cause-specific Cox proportional hazard regression models. The associations of development of advanced HF with risks of hospitalization and mortality were examined using the Andersen-Gill and Cox models, respectively. Results: There were 4597 residents with incident HF from 2007 to 2017. The cumulative incidence of advanced HF was 11.5% (95% CI, 10.5%–12.5%) at 6 years after incident HF diagnosis overall and was 14.4% (95% CI, 12.3%–16.9%), 11.4% (95% CI, 8.9%–14.6%), and 11.7% (95% CI, 10.3%–13.2%) in patients with incident HF with reduced, mildly reduced, and preserved ejection fraction, respectively. Key demographics, comorbidities, and echocardiographic characteristics were independently associated with the development of advanced HF. Development of advanced HF was associated with increased risks of all-cause hospitalization (adjusted hazard ratio, 3.0 [95% CI, 2.7–3.4]; P <0.001), HF hospitalization (hazard ratio, 10.2 [95% CI, 8.7–12.1]), all-cause mortality (hazard ratio, 5.0 [95% CI, 4.5–5.6]; P <0.001), and cardiovascular mortality (hazard ratio, 7.8 [95% CI, 6.7–9.1]). Conclusions: In this population-based study, development of advanced HF was common and was associated with markedly increased morbidity and mortality.
Feasibility and Reproducibility of Multifrequency Magnetic Resonance Elastography in Healthy and Diseased Pancreases
Song, Qike , Shi, Yu , Gao, Feng , Yin, Meng , Yang, Rui , Liu, Yuanyuan , Zhong, Shiling, Hong, Yang , Yin, Meng , Zhong, Shiling, Shi, Yu

Mayo Clinic

Journal of Magnetic Resonance Imaging | March 25, 2022 | Volume: 56 | Issue: 6 | Pages: 1769-1780

10.1002/jmri.28158 | PMID 35332973 Get It

BackgroundThe feasibility and reproducibility of multifrequency MR elastography (MRE) for diagnosing pancreatic ductal adenocarcinoma (PDAC) have not been reported.PurposeTo determine the feasibility and reproducibility of multifrequency MRE for assessing pancreatic stiffness in healthy and diseased pancreases.Study typeProspective.SubjectsA total of 40 healthy volunteers and 10 patients with PDAC were prospectively recruited between March 2018 and October 2021.Field strength/sequenceA 3.0‐T pancreatic MRE at frequencies in the order of 30, 40, 60, 80, and 100 Hz.AssessmentBody mass index (BMI) and wave distance of the healthy pancreas and PDAC were measured. Image quality was assessed using the image quality score (IQS: 1–4, ≥3 were considered diagnostic quality). Three readers independently performed the pancreatic stiffness and IQS assessments to evaluate reproducibility.Statistical testsLogistic regression analyses were performed to determine variables that influenced IQS. Statistical significance was set at P <0.05. Levels of inter‐ and intrarater agreement were assessed using intraclass correlation coefficients (ICC) and Cohen's kappa coefficient (κ). Good reproducibility was set at ICC and κ ≥ 0.8.ResultsIn logistic regression analysis, a diagnostic IQS in healthy volunteers was independently associated with a lower BMI (odds ratio [OR] = 0.89 kg/m−2), shorter wave distance (OR = 0.70 cm−1), and lower frequency (30 and 40 Hz: OR = 170.01 and 96.02). In PDAC, frequency was the only independent factor for diagnostic IQS (30–60 Hz: OR = 46.18, 46.18, and 17.20, respectively) with 100 Hz as a reference. In healthy volunteers, good reproducibility was observed at 30 and 40 Hz. In PDAC, good reproducibility was observed at 30–60 Hz.Data conclusionMRE at 30 and 40 Hz provides diagnostic wave images and reliable measurements of pancreatic stiffness in healthy volunteers. MRE at 30–60 Hz is acceptable for PDACs (IQS ≥ 3, ICC and κ ≥ 0.80).Evidence Level1Technical EfficacyStage 2
A Randomized, Placebo-Controlled, Split-Neck Trial of Hyaluronic Acid Filler for Static Horizontal Neck Rhytides Using Either a Cannula or Needle
Siperstein, Robyn, Cotofana, Sebastian, Barnes, Megan, Nestor, Elizabeth, Meran, Suzanne, Grunebaum, Lisa, Siperstein, Robyn, Cotofana, Sebastian, Barnes, Megan, Nestor, Elizabeth, Meran, Suzanne, Grunebaum, Lisa

Mayo Clinic

Dermatologic Surgery | March 25, 2022 | Volume: 48 | Issue: 4 | Pages: 423-428

10.1097/dss.0000000000003391 | PMID 35333199 Get It

BACKGROUND Hyaluronic acid (HA) fillers have been studied extensively on the face; however, their safety and efficacy on the neck has not yet been evaluated in a prospective trial in the United States. OBJECTIVE Analyze the efficacy and safety of a HA filler for static horizontal neck rhytides using either a cannula or needle. MATERIALS AND METHODS Twenty-six subjects were randomized to receive up to 1 mL of the HA filler Restylane Refyne (HARR, n = 20) or saline (n = 6) using a cannula on one side and a needle on the other with optional repeat treatment. Subjects were graded using the Transverse Neck Line Scale, Canfield photography, and the Global Aesthetic Improvement Scale. RESULTS A significant improvement 30 days after the last treatment was achieved on the Transverse Neck Line Scale when comparing HARR with saline according to the blind evaluator, subjects, and investigator without any significant side effects. In addition, the blind evaluator, subjects, and investigator rated the side of the neck injected with a needle as having significantly greater improvement than the cannula. CONCLUSION The hyaluronic acid filler, Restylane Refyne, achieved significant improvement in static horizontal neck rhytides using either a cannula or needle without any serious side effects, although the needle was more effective.
CPI Physics in Imaging Special Edition Module
Jokerst, Clinton, Sharma, Puneet , Vedantham, Srinivasan , Covington, Matthew F. , Eisenbrey, John Robert , Saranathan, Manojkumar

Mayo Clinic

Continuous Professional Improvement | March 25, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.54057/cpi.ph2022 Get It

Use of Botulinum Toxin and Hyaluronic Acid Filler to Treat Oral Involvement in Scleroderma
Cumsky, Helen J.L., Pham, Michael M., Hoss, Elika, Pham, Michael M. , Cumsky, Helen J.L., Pham, Michael M., Hoss, Elika

Mayo Clinic

Dermatologic Surgery | March 25, 2022 | Volume: 48 | Issue: 6 | Pages: 698-699

10.1097/dss.0000000000003420 | PMID 35333209 Get It

Lithium in patients with chronic kidney disease – To continue versus discontinue?
Pahwa, Mehak , Singh, Balwinder , Singh, Balwinder

Mayo Clinic

Bipolar Disorders | March 25, 2022 | Volume: 24 | Issue: 5 | Pages: 549-550

10.1111/bdi.13209 | PMID 35332966 Get It

A Genome-Wide Gene-Based Gene–Environment Interaction Study of Breast Cancer in More than 90,000 Women
Chen, Hongjie , Middha, Pooja , Bolla, Manjeet K. , Wang, Qin , Michailidou, Kyriaki , Hopper, John L. , Shibli, Rana , Aronson, Kristan J. , Hodge, James M. , Brenner, Hermann , Hoppe, Reiner , Lo, Wing‐Yee, Mannermaa, Arto , Kosma, Veli‐Matti , Jung, Audrey , Haiman, Christopher A. , Simard, Jacques , Goldberg, Mark S. , García‐Closas, Montserrat , Yang, Rose, Evans, D. Gareth , Howell, Anthony , Orr, Nick , Wang, Sophia , Easton, Douglas F. , Chang‐Claude, Jenny , Lindström, Sara , Winham, Stacey, Evans, D Gareth , Brenner, Hermann , Kapoor, Pooja Middha , García-Closas, Montserrat , Michailidou, Kyriaki , Hodge, James M , Simard, Jacques , Wang, Sophia S , Jung, Audrey Y , Orr, Nick , Wang, Xiaoliang , Su, Yu-Ru , Dennis, Joe , Dunning, Alison M. , Lush, Michael J. , Pharoah, Paul D.P. , Southey, Melissa C. , Koutros, Stella , Freeman, Laura E. Beane , Stone, Jennifer , Rennert, Gad , Murphy, Rachel A. , Guénel, Pascal , Truong, Thérèse , Teras, Lauren R. , Canzian, Federico , Kaaks, Rudolf , Arndt, Volker , Behrens, Sabine , Becher, Heiko , Giles, Graham G. , Maskarinec, Gertraud , Scott, Christopher G. , Winham, Stacey J. , Zheng, Wei , Long, Jirong , Troester, Melissa A. , Love, Michael I. , Peng, Cheng , Tamimi, Rulla M. , Eliassen, A. Heather , Figueroa, Jonine D. , Ahearn, Thomas U. , Hall, Per N , Czene, Kamila , Wolk, Alicja , Sandler, Dale P. , Taylor, Jack A. , Swerdlow, Anthony J. , Lacey, James V. , Olsson, Håkan , Milne, Roger L. , Hsu, Li , Kraft, Peter

Mayo Clinic

Cancer Research Communications | March 25, 2022 | Volume: 2 | Issue: 4 | Pages: 211-219

10.1158/2767-9764.crc-21-0119 | PMID 36303815 Get It

Genome-wide association studies (GWAS) have identified more than 200 susceptibility loci for breast cancer, but these variants explain less than a fifth of the disease risk. Although gene–environment interactions have been proposed to account for some of the remaining heritability, few studies have empirically assessed this. We obtained genotype and risk factor data from 46,060 cases and 47,929 controls of European ancestry from population-based studies within the Breast Cancer Association Consortium (BCAC). We built gene expression prediction models for 4,864 genes with a significant (P &lt; 0.01) heritable component using the transcriptome and genotype data from the Genotype-Tissue Expression (GTEx) project. We leveraged predicted gene expression information to investigate the interactions between gene-centric genetic variation and 14 established risk factors in association with breast cancer risk, using a mixed-effects score test. After adjusting for number of tests using Bonferroni correction, no interaction remained statistically significant. The strongest interaction observed was between the predicted expression of the C13orf45 gene and age at first full-term pregnancy (PGXE = 4.44 × 10−6). In this transcriptome-informed genome-wide gene–environment interaction study of breast cancer, we found no strong support for the role of gene expression in modifying the associations between established risk factors and breast cancer risk. Our study suggests a limited role of gene–environment interactions in breast cancer risk.
Letter: The Modern Evolution of Simulations in Endovascular Neurosurgery—A Short Review
Ghozy, Sherief , Ghozy, Sherief , Azzam, Ahmed Y , Dmytriw, Adam A.

Mayo Clinic

Neurosurgery | March 25, 2022 | Volume: 90 | Issue: 6 | Pages: e182-e183

10.1227/neu.0000000000001946 | PMID 35333211 Get It

The development of ultra–high field MRI guidance technology for neuronavigation
Rusheen, Aaron E., Goyal, Abhinav, Owen, Robert L., Berning, Elise M., Bothun, Dane T., Giblon, Rachel E., Blaha, Charles D., Welker, Kirk M., Huston, John, Bennet, Kevin E., Oh, Yoonbae, Fagan, Andrew J., Lee, Kendall H., Giblon, Rachel , Rusheen, Aaron E., Goyal, Abhinav, Owen, Robert L., Berning, Elise M., Bothun, Dane T., Blaha, Charles D., Welker, Kirk M., Huston, John, Bennet, Kevin E., Oh, Yoonbae, Fagan, Andrew J., Lee, Kendall H.

Mayo Clinic

Journal of Neurosurgery | March 25, 2022 | Volume: 137 | Issue: 5 | Pages: 1265-1277

10.3171/2021.11.jns211078 | PMID 35334465 Get It

OBJECTIVE Magnetic resonance imaging at 7T offers improved image spatial and contrast resolution for visualization of small brain nuclei targeted in neuromodulation. However, greater image geometric distortion and a lack of compatible instrumentation preclude implementation. In this report, the authors detail the development of a stereotactic image localizer and accompanying imaging sequences designed to mitigate geometric distortion, enabling accurate image registration and surgical planning of basal ganglia nuclei. METHODS Magnetization-prepared rapid acquisition with gradient echo (MPRAGE), fast gray matter acquisition T1 inversion recovery (FGATIR), T2-weighted, and T2*-weighted sequences were optimized for 7T in 9 human subjects to visualize basal ganglia nuclei, minimize image distortion, and maximize target contrast-to-noise and signal-to-noise ratios. Extracranial spatial distortions were mapped to develop a skull-contoured image localizer embedded with spherical silicone fiducials for improved MR image registration and target guidance. Surgical plan accuracy testing was initially performed in a custom-developed MRI phantom (n = 5 phantom studies) and finally in a human trial. RESULTS MPRAGE and T2*-weighted sequences had the best measures among global measures of image quality (3.8/4, p < 0.0001; and 3.7/4, p = 0.0002, respectively). Among basal ganglia nuclei, FGATIR outperformed MPRAGE for globus pallidus externus (GPe) visualization (2.67/4 vs 1.78/4, p = 0.008), and FGATIR, T2-weighted imaging, and T2*-weighted imaging outperformed MPRAGE for substantia nigra visualization (1.44/4 vs 2.56/4, p = 0.04; vs 2.56/4, p = 0.04; vs 2.67/4, p = 0.003). Extracranial distortion was lower in the head’s midregion compared with the base and apex ( 1.17–1.33 mm; MPRAGE and FGATIR, p < 0.0001; T2-weighted imaging, p > 0.05; and T2*-weighted imaging, p = 0.013). Fiducial placement on the localizer in low distortion areas improved image registration (fiducial registration error, 0.79–1.19 mm; p < 0.0001) and targeting accuracy (target registration error, 0.60–1.09 mm; p = 0.04). Custom surgical software and the refined image localizer enabled successful surgical planning in a human trial (fiducial registration error = 1.0 mm). CONCLUSIONS A skull-contoured image localizer that accounts for image distortion is necessary to enable high-accuracy 7T imaging–guided targeting for surgical neuromodulation. These results may enable improved clinical efficacy for the treatment of neurological disease.
Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance)
Kulke, Matthew H. , Ou, Fang-Shu, Niedzwiecki, Donna, Huebner, Lucas, Kunz, Pamela L. , Kennecke, Hagen F, Wolin, Edward M, Chan, Jennifer A, O’Reilly, Eileen M, Meyerhardt, Jeffrey A, Venook, Alan, Niedzwiecki, Donna , Meyerhardt, Jeffrey A. , Kunz, Pamela , Meyerhardt, Jeffrey A , Niedzwiecki, Donna , Kulke, Matthew H , Ou, Fang-Shu, Huebner, Lucas, Kennecke, Hagen F, Wolin, Edward M, Chan, Jennifer A, O’Reilly, Eileen M, Venook, Alan

Mayo Clinic

Endocrine-Related Cancer | March 25, 2022 | Volume: 29 | Issue: 6 | Pages: 335-344

10.1530/erc-21-0239 | PMID 35324465 Get It

Treatment with the MTOR inhibitor everolimus improves progression-free survival (PFS) in pancreatic neuroendocrine tumors (pNETs), but it is not known if the addition of a VEGF pathway inhibitor to an MTOR inhibitor enhances antitumor activity. We performed a randomized phase II study evaluating everolimus with or without bevacizumab in patients with advanced pNETs. One hundred and fifty patients were randomized to receive everolimus 10 mg daily with or without bevacizumab 10 mg/kg i.v. every 2 weeks. Patients also received standard dose of octreotide in both arms. The primary endpoint was PFS, based on local investigator review. Treatment with the combination of everolimus and bevacizumab resulted in improved progression-free survival compared to everolimus (16.7 months compared to 14.0 months; one-sided stratified log-rank P = 0.1028; hazard ratio (HR) 0.80 (95% CI 0.56–1.13)), meeting the predefined primary endpoint. Confirmed tumor responses were observed in 31% (95% CI 20%, 41%) of patients receiving combination therapy, as compared to only 12% (95% CI 5%, 19%) of patients receiving treatment with everolimus ( P = 0.0053). Median overall survival duration was similar in the everolimus and combination arm (42.5 and 42.1 months, respectively). Treatment-related toxicities were more common in the combination arm. In summary, treatment with everolimus and bevacizumab led to superior PFS and higher response rates compared to everolimus in patients with advanced pNETs. Although the higher rate of treatment-related adverse events may limit the use of this combination, our results support the continued evaluation of VEGF pathway inhibitors in pNETs.